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Drug patenting would be an effective tool to encourage introducing new drugs for prevention and treatment of diseases. 
The main goal of drug patenting is to protect all the interests of inventor and try to create a secure and confident way to 
encourage those who are involved in pharmaceutical industries. However, some pharmaceutical companies by using 
different strategies like, combination, finding new medical use, new formulation or slight changes in old drugs, abuse this 
tool to extend their patents (patent ever-greening) and obtain more economic advantages. These types of drugs, due to lack 
of full requirements of an invention such as novelty and inventive step, cannot be considered as new drugs, therefore, cannot 
be patented. Pharmaceutical patent ever-greening is in contradicted with the spirit of the innovation, invention and 
commercialization. By preventing the introduction of generic drugs into the market, it might endanger public health via 
continue selling of brand drugs with exorbitant prices. Pharmaceutical patent ever-greening is a global issue because 
practical approaches to patent ever-greening are currently seen in both developing and developed countries and it imposes a 
substantial burden on the public health. For this reason, passing a law to ban ever-greening of pharmaceutical patents is 
essential in all countries of in the world. 
Keywords: TRIPS Agreement, US Food and Drug Administration, WHO Essential Medicines List, public health, patent, 
ever-greening, drug modification, combined drugs, fixed-dose combinations, direct-to-consumer advertising 
Despite the presence of the United Nations Charter 
(1945), the Universal Declaration of Human Rights 
(1948) and the Constitution of World Health 
Organization (1948) at global level and many similar 
rights at regional and national levels, according to the 
report of the United Nations Secretary General in 
2016, due to rising costs and prices of health 
technologies, millions of people in all countries don’t 
have access to many medicines, diagnostics, medical 
devices and vaccines.
1
 
Restriction and lack of access to essential drugs  
is a global issue
2
 and accordingly the use of generic 
drugs has become a global need. The use of generic 
drugs has direct effect on cost savings and these 
savings can be massive for health care systems. For 
example, even in relatively rich nations such as the 
USA, it has saved more than US$ 1.2 trillion to the 
US health care system between 2003 and 2012.
3
 Also, 
European Commission in 2009 estimated that 
taxpayers in European countries lost over €3 billion 
(US$ 3.4 billion) per year due to postponing of 
generic drugs production (the findings were 
confirmed by a 2014 study).
4 
Pharmaceutical Patent Ever-greening (PPE) 
virtually is a set of various legal, business  
and technological ways and strategies which  
are used by pharmaceutical patent owners in order  
to extend their patents. Some of these strategies 
include: pay-for-delay settlement, switching to over 
the counter (OTC), partnerships with generic 
manufacturers or establishment of generic units.  
But, the most affordable and used strategy is 
intentional minor modifications of old drugs in  
order to obtain multiple patents on the same  
drug and accordingly earn more economic 
advantages.
5 
There are several strategies for  
ever-greening of drug patents, but the main  
purpose of the present study is especially to 
investigate the patentability of controversial seven 
major categories of pharmaceutical products 
including: enantiomers, combination drugs, new 
medical uses, new formulations, metabolites,  
new routes of administration and polymorphs  
of existing drugs. This study tries to answer  
the questions; Can a minor modification of an  
old drug change it to a new drug?; Are these types  
of drugs fully compliant with the patent  
requirements? 
——————— 
†
Email: tafreshih@yahoo.com 
J INTELLEC PROP RIGHTS, MAY-JULY 2019 
 
 
104 
Patent  
World Intellectual Property Organization (WIPO) 
defines patent as: ''A patent is an exclusive right 
granted for an invention, which is a product or a 
process that provides, in general, a new way of doing 
something, or offers a new technical solution to a 
problem". The patent right is territorial and the 
exclusive right is granted to a patent owner for 
generally 20 years from the filing date in accordance 
with the laws and regulations of the particular country 
or region that patent owner issues the patent.
6 
That 
means, there is not a single patent law all over the 
world and each country can establish a patent law in 
accordance with its own conditions. Also, by expiring 
a patent, the protection will be finished and patent 
holder has not any right to keep this interest and at 
this stage, the public can be benefited from production 
of generic drugs. Requirements of an invention in 
order to get a patent are:  
(i) Novelty: In patent law, novelty is a part of the 
legal test to ensure that the invention has not been 
available to the public by any means before the 
filing date. The goal of the novelty requirement is 
to avoid double or multiple patents for the same 
or similar inventions.  
(ii) Inventive step (non-obviousness): Seeking 
problem-solution approach in order to distinguish, 
if an invention is new or it is obvious to a skilled 
person in the art. 
(iii)  Industrial applicability (utility) and sufficient 
disclosure: An invention shall be taken to be 
capable of industrial application, if it can be made 
or used in any kind of industry. Also, an inventor 
must describe the invention to the public in such 
full and complete details to enable a person with 
common skills in the art to make and use the 
invention.
7 
 
Originator and Generic Drug Manufacturers 
Nowadays, producing medicine in the world has 
been generally recognized under two different 
methods. (i) Production of a new medicine based on 
new research and development (R&D), patenting it 
under patent laws and keeps the exclusive right for 
originator manufacturer (patent holder) for a certain 
period of time (20 years) and with a brand name will 
be sold out. (ii) Production of medicine when the drug 
patent expired and no more protection vested in 
inventor or exclusive right has no more effect; thus 
generic medicines by generic manufacturers will be 
produced and marketed.
8
 
In comparison with brand drugs, generic drugs 
have much less expensive price (20-90% cheaper than 
branded drugs) and accordingly playing a vital role in 
supplying essential drugs especially in low and 
middle income countries.
8-9 
There is a big challenge 
between these two types of drug manufacturers. 
Originator manufacturers try to grant their inventions 
as patents and by using different methods attempt to 
prolong the protection time of these patents 
exclusively. In contrast, generic manufacturers as a 
competitor try to examine the licenses of originator 
companies precisely and if these patent registrations 
have no consistency with law and regulations of the 
litigation of the countries, demanding to repeal the 
execution of the patent protection. Also, they always 
impatiently waiting to expire the protection time of 
patents and produce generic drugs. In the following 
section, some of the methods which are used by 
originator manufacturers to prolong drug patents, 
have been discussed. 
 
Enantiomers 
Because of high cost of introducing new drugs  
into the market, originator pharmaceutical companies 
pursue to introduce and patent enantiomer drugs.  
The policy is followed just to get benefit from  
new patent interests again. For example, Prilosec
® 
(omeprazole) and Nexium
® 
(esomeprazole) are two 
drugs that being used to control gastric hyperacidity. 
They both belong to a class of medications, called 
proton pump inhibitors (PPIs) which work by 
decreasing the secretion of acid in stomach. When 
Prilosec
®’s patent has been expired, Astra Zeneca 
company introduced a drug named Nexium
® 
in  
2001 and has been benefited a big financial gain  
only in this year ($623 million).
10-11
 
The difference between two drugs is that Prilosec
®
 
is an equal (racemic) mixture of R- and Senantiomers 
but Nexium
®
 only consists of S-enantiomer. In other 
words, they are two isomers of one drug and they are 
only mirror images of each other. Simply, Nexium
®
 is 
Prilosec
®
 without R-enantiomer. 
Later, some studies have shown that Nexium
® 
has 
no superior efficacy over prilosec
®
.
12-13 
Based on 
patent laws and regulations, originator manufacturers 
should never ever been able to patent a drug twice 
with the same active ingredient but Astra Zenecahas 
done it and prevented generic production of the drug. 
On the other hand, different studies have revealed that 
single enantiomer drugs had not any superiority over 
the racemic old drugs and in some cases, undesirable 
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effects have also observed in comparison with 
racemic old drugs. Some of the FDA approved 
medications that have been studied, include: 
dexlansoprazole, levoleucovorin, levocetirizine, 
armodafinil, arformoterol, eszopiclone, escitalopram, 
dexmethylphenidate, and esomeprazole. Between 
2001 and 2011, these drugs have been imposed 
US$6.3 billion on the US Medicaid programs.
14-15 
 
Combination of Existing Drugs 
Combined drugs or fixed-dose combinations 
(FDCs) are the result of putting two or more 
medicines together in a single dosage form to treat a 
single disease (such as, cancer or diabetes) or two 
closely related diseases (such as, hyperlipidemia and 
hypertension). It is claimed that combined drugs have 
the following benefits: overall lower costs in 
comparison to multiple and separate drugs, improving 
patient compliance and having higher efficacy with 
lower risk of adverse reactions.
16-17 
However, are 
these all the facts? 
 
Combined Drugs and Side Effects 
Combination of clopidogrel with aspirin can reduce 
the risk of cardiovascular events but it is associated 
with increasing risk of bleeding in comparison with 
aspirin alone.
18 
 
Combined Drugs and Lower Cost 
In paper published in Medical Journal of Australia, 
Australian researchers found that maybe combined 
drugs are initially cheaper than individual therapies, 
but more costs are totally paid by the government and 
the payers. It is worth mentioning that Australia is 
spending US $ 600 million per year for heart diseases 
and diabetes combination therapies.
19 
 
Combined Drugs and Higher Efficacy 
Combined drugs do not necessarily have a higher 
efficacy than separate drugs. For example, the results 
of a meta-analysis indicated that combined 
antihypertensive drugs don’t have any advantage in 
blood pressure control and reduction of adverse 
effects.
20
 A comparison of antihypertensive drugs, 
telmisartan and S-amlodipine, resulted the same 
efficacy and safety for both combined and separate 
administration of these drugs.
21
 Also, unapproved 
formulations of antibiotic combined drugs and 
accordingly rising antimicrobial resistance and health 
crisis have been reported by Indianresearchers.
22 
Evaluation the safety and rationale use of antibacterial 
combined drugs in the private sector of eight Latin 
American countries (Argentina, Brazil, Chile, 
Colombia, Mexico, Peru, Uruguay and Venezuela) 
between 1999 and 2009 showed that the majority of 
these combined drugs didn’t have therapeutic 
effects.
23 
The results of 13 randomized controlled 
trials analysis from 1987 to 2015 on efficacy, safety 
and acceptability (including treatment failure, relapse 
of the disease, death, serious adverse events and 
adverse events that led to discontinuation of therapy) 
of anti tuberculosis drugs in both separate and 
combined forms revealed similar effects for treatment 
of newly diagnosed pulmonary tuberculosis.
24 
Even 
researchers being aware that combined drugs should 
be only prescribed after treatment failure with 
separate drugs, cautious is required especially in 
elderly patients who are suffering from multiple 
concurrent diseases and regular reassessment of these 
drugs is urged.
25
 
Combined drugs have some disadvantages include: 
lack of dose flexibility, enhanced drug interactions 
between drugs and excipients, difficult in identifying 
of causative drug(s) responsible for side effects and 
boost of toxicity.
26-28 
 
New Medical Uses of Old Drugs 
New medical use or drug repositioning (drug 
repurposing, drug retasking, drug rescuing, therapeutic 
switching, drug recycling or drug reprofiling) is the use 
of old drugs for new medical indications (to treat 
another disease). Drug repositioning is an efficient 
approach, in order to save money, time and maximize 
financial return of initial investment, because many 
existing drugs have: 1) determined formulations and 
established manufacturing processes, 2) extensive data 
about absorption, distribution, metabolism, excretion 
and toxicity, 3) passed clinical trials and less likely to 
fail future clinical trials because of side effects and 4) 
post marketing surveillance safety data.
29-30 
Drug 
repurposing extends to all areas of medicine and there 
are many examples. Table 1 shows some examples of 
repositioned drugs. 
Even withdrawn drugs (due to safety 
considerations) reappear in drug repositioning. 
Thalidomide, which was initially developed as a 
sedative and then used as a treatment for nausea and 
vomiting of pregnancy, caused over 10,000 of severe 
birth defects (phocomelia) in children between 1957 
and 1962.
31 
It was withdrawn due to phocomelia, but 
it was approved by the US Food and Drug 
Administration (FDA) for treatment of leprosy 
complications and multiple myeloma (bone marrow 
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cancer).
32 
It is currently used for treatments of different 
diseases including: leprosy, multiple myeloma, Crohn’s 
disease, Behcet’s disease, HIV and lupus. Tragically, 
after the thalidomide disaster in the late 1950s and the 
early 1960s, the similar event has occurred again in a 
fewer Brazilian children due to leprosy treatment of 
their mothers (who are not informed of the dangers of 
the drug) with thalidomide.
31 
 
New Formulations of Old Drugs 
Venlafaxine (an antidepressant drug and marketed 
as Effexor
®
) is an immediate release tablet and due to 
short half life, generally prescribed in two or three 
times daily. It found out to cause side effects (nausea 
and dizziness).However, when the drug will be 
provided in extended release form (Effexor XR
®
), it is 
gradually released in the body and would be taken once 
daily and consequently, reducing side effects.
33-34
 
But efficacy and tolerabilitty of extended release 
(XR) formulation of venlafaxine is a subject of 
controversy. For example, the results of two studies 
demonstrated that extended release formulation of 
venlafaxine is effective and well tolerated
35-36
, but 
with respect to antidepressant efficacy, the extended 
release formulation was equivalent to the immediate 
release formulation according to a comparative 
analysis study.
37 
Venlafaxine XR was recommended 
for suspension by the Committee for Medicinal 
Products for Human Use (CHMP) on 21 May 2015 
and has been banned in some European countries such 
as Germany, Malta, Poland, Portugal, the Netherlands 
and the United Kingdom.
38
 
There are other examples. Extended release 
formulation of antidepressant drug Prozac
® 
and  
anti-diabetic drug Glucophage
® 
entered into the 
pharmaceutical market by Lilly and Bristol-Myers 
Squibb respectively when they faced the expiration of 
their patents for Prozac
® 
and Glucophage
®
. 
 
Metabolite of Old Drugs 
Venlafaxine is extensively metabolized to an  
active metabolite, O-desmethylvenlafaxine or 
brieflydesvenlafaxine by the liver. This means, if you 
take venlafaxine, your body breaks it down into 
desvenlafaxine. Definitely, venlafaxine is the origin 
and source of desvenlafaxine and both compounds are 
closely related to each other.
33 
Desvenlafaxine has no 
additional benefits for patients and in comparison  
to venlafaxine XR, both drugs have the same 
pharmacologic and pharmacokinetic profiles.Also, 
both drugs have shown the similar side effects and 
tolerability in clinical trials. But, the only significant 
difference between these drugs, is the price (US $ 
2,000 yearly for brand name of desvenlafaxine and 
US $150 yearly for generic venlafaxine XR, based on 
average wholesale price).
39-41
 Prescription of Pristiq
® 
(desvenlafaxine) instead of off-patent Effexor XR
®
, 
costs more than A$21 million per year to Australian 
taxpayers based on reports of prescription volumes in 
2013-2014.
41
 
Desvenlafaxine is marketed as Pristiq
®
 by Pfizer. 
Effexor XR
® 
and Pristiq
® 
extend the life of Effexor
®
 
patent. It is important to note, there is not any generic 
version of Pristiq
®
 until August of 2023, when the 
Pristiq
® 
patent expires.
41 
 
New Routes of Administration for Old Drugs 
Imitrex
® 
(Sumatriptan, a migraine drug),originally 
formulated in tablet form and for oral administration. 
Then it was reformulated, patented and obtained  
the FDA approval for intranasal delivery (nasal 
administration) by GlaxoSmithKline (GSK).The 
original patent of the drug expired in 2006, but the 
company extended its patent protection time until 
February of 2009 by presentation of nasal spray of the 
drug. The drug faced worldwide total sales of over 
US$1 billion in 2006 for GSK.
42 
 
Polymorphs 
The term of “polymorphism” is applied in different 
fields such as Biology, Computer Science and 
Medicine, but what is the definition of polymorphism 
in chemistry? Simply, polymorphism is the existence 
of different kinds of crystal structure of the same 
Table 1 — Repositioned drugs for new medical indications 
Drug (Generic name) Original indication New indication (Brand name) 
Acetyl salicylic acid (ASA) Pain, Inflammation and Fever Antiplatelet (Aspirin®) 
Minoxidil Hypertension Hair loss (Rogaine®) 
Sildenafil Hypertension Erectile dysfunction (Viagra®), Pulmonary hypertension (Revatio®) 
Finasteride Prostate hyperplasia Hair loss (Propecia®) 
Raloxifene Cancer Osteoporosis (Evista®) 
Methotrexate Cancer Psoriasis, Rheumatoide artheritis (Rasuvo®, Trexall™, Otrexup™) 
Duloxetine Depression Chronic pain disorders (Cymbalta®, Irenka™) 
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chemical compound and each of these crystalline 
structures, is called polymorph. Polymorphs have 
different physical and chemical properties. For 
instance, diamond and graphite, both are made of pure 
carbon, but their physical and chemical properties are 
different drastically.
43 
In pharmaceutical industries, 
polymorphism of an active pharmaceutical ingredient 
(API) and accordingly its physical and chemical 
properties, is critical for successful drug development 
and significantly affects on variety of API properties, 
including production of API, flowability, tableting, 
dissolution rate, solubility, stability and even efficacy 
and toxicity.
44
 
But what would be the other side of the coin? It 
should be noted that change in polymorphism is not 
necessarily associated with enhancement of drug 
efficacy. For example, a more stable polymorph of a 
drug may enhance the expiration date of the drug or 
greater tensile strength of Sulfamerazine form-I 
polymorph tends to better tablet ability and 
compressibility.
44-45 
Also, approximately 51% of the 
new molecular entities approved by the FDA between 
1985-2005 with at least one patent, have claims to 
polymorphs, isomers, pro-drugs, esters or salts. 
Interestingly, independent secondary patents (patents 
with only secondary claims and no chemical 
compound claims) on polymorphs, isomers, pro-drug, 
ester, and/or salt claims add an average of 6.3 years 
(5.3 to 7.3 years) of patent life.
46 
Through, the strategy 
of polymorphs patenting and in the example of 
atorvastatin, Pfizer extended market exclusivity of the 
drug for additional 6 years (from 2011 to 2017) by 
disclosing the drug new polymorphs as a separate 
patent or in the case of lumacaftor, Vertex 
Pharmaceuticals increased patent life of the drug for 
additional 4 years (from 2026 to 2030) by holding 14 
patents with a polymorph patent.
45 
 
Efficacy, Toxicity and Price of New Drugs 
Sometimes, it is claimed that these types of drugs 
are more efficient, less toxic and have less price in 
comparison with original ones. According to the 
WHO Report, drugs that being categorized as a low or 
without efficacy by the FDA, have approximately the 
same price of the original drugs in the USA and even 
double price of original drugs in Sweden. Cockburn 
and Anis compared the price of anti-arthritic drugs 
just based on their toxicity and efficacy in 1998. The 
result was vice-versa, by increasing price, their 
efficacy were decreased and their toxicity were 
increased.
47
 
According to the 2016 annual report, even a 
successful country at controlling the price of patented 
drugs such as Canada, after the United States and 
Switzerland, is the third highest priced country among 
Organization for Economic Cooperation and 
Development (OECD) countries.
48 
Therefore, 
introduction of new patented drugs, does not 
necessarily mean that they are more efficient, less 
toxic and cheaper than original ones. 
 
TRIPS and Drug Patenting 
Before the adoption of World Trade Organization 
(WTO) Agreement on Trade-related Aspects of 
Intellectual Property Rights (TRIPS) in 1994, over 50 
countries in the world did not support drug patenting; 
so many other countries only supported the process of 
producing medicines, but not new drugs.
49-50
 All these 
demarcations and limitations were only to keep the 
price of drugs down and let the generic manufacturers 
to produce and supply of essential drugs in order to 
support of public health. 
Over 15 years, after development and release of the 
WHO Essential Medicines List and supporting 
generic drugs production in the developing countries, 
TRIPS Agreement, partially under pressure from the 
USA, was adopted in 1994 and came into effect in 
January 1995.
3 
Interestingly, TRIPS is administered 
by the WTO and not by the WIPO. TRIPS invokes so 
many laws and regulations for the first time in regards 
of drug patenting, such as, prohibition of excluding of 
drug patenting and executing the protection time of 
patents for 20 years. Even, TRIPS-plus standards 
provide stronger support for intellectual property 
rights. The results of these standards is increasing in 
economic benefits of the patent holders and 
decreasing in public access to knowledge and 
technology.
51
 
It is claimed that TRIPS flexibilities (two of the 
most important ones, compulsory licensing and 
parallel importation) and the Declaration on TRIPS 
and Public Health signed in Doha in 2001 (the Doha 
Declaration) provide access to medicines and 
reinforce to promote public health solutions in 
developing countries, respectively. However, are 
these flexibilities practical? 
 
Compulsory Licensing 
Paragraph (f) under Article 31 of the TRIPS 
Agreement specifies that: “any such use shall be 
authorized predominantly for the supply of the 
domestic market of the Member authorizing  
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such use”.52 Implementation of compulsory  
licensing in the developing countries is very  
difficult because this flexibility is considered  
to supply of drugs for the domestic market and  
these countries don’t have realistically a suitable  
and strong pharmaceutical industrial infrastructure. 
On the other hand, according to the Paragraph (b) of 
the Article and in the best situation, compulsory 
licensing is practical in situations of national 
emergency (without authorization from the right 
holder) and it is unusable for routine supply of 
essential and expensive drugs. Also, adequate 
compensation must be paid to the patent holder in the 
event of compulsory licensing.
52-55 
 
Parallel Importing 
Parallel imports involve the import and resale of 
goods at a cheaper price from another country without 
the express permission of the right holder. But, there 
are barriers to parallel importing despite the promise 
of the Article 6 and the reaffirmations provided by the 
Doha Declaration, such as, economical and political 
pressure and fear of incurring in other trade areas  
due to powerful trading partnersfury;
56-57
 economic 
retaliatory actions of big economical powers against 
developing countries (threat to trade sanctions of 
South Africa by the United States in 1997 in order to 
repeal a section of the Medicines and Related 
Substances Control Amendment Act which allowed 
compulsory licensing and parallel importing in spite 
of compliance with the TRIPS Agreement);
53
 
insufficient demand; difficulties in generic drugs 
registration; undermining the Doha Declaration and 
the Paragraph; Decision by enhancement of 
intellectual property protections in regional and 
bilateral trade agreements such as TRIPS-Plus 
provisions for medicines; and lack of legislative and 
regulatory requirements both for importing and 
exporting in developing countries.
58
 
 
Discussion 
From a human health rights perspective, access to 
drugs and medical devices, are essential in developing 
countries.
3,59
 Production, import and export of generic 
drugs due to their cheaper prices, are the center of 
attention both for health system decision makers and 
generic manufacturers in all countries of the world 
especially in developing countries. But, generic drugs 
cannot be produced prior to patents expiration of 
brand drugs. On the other hand, monopolism and the 
exclusive rights of producing, using, selling and 
distributing are only granted for patent owners during 
patent protection period (20 years) and upon 
expiration of a branded drug's patents, these 
monopoly and exclusive rights will be disappeared. 
For this reason, originator manufacturers by using 
different strategies attempt to keep these exclusive 
rights, extend the patent life of their drugs (more than 
20 years) and continue to prevent or to delay generic 
manufacturers' entry. 
In this paper, review and evaluation of seven 
different types of drug modifications have shown that 
in all cases, regardless of their efficacy, toxicity and 
price, these modified drugs cannot be patented due to 
lack of novelty and inventive step.
60
 For example, 
according to the patent definition and requirements of 
an invention, what is the novelty of enantiomers, 
drugs metabolites, polymorphs and new routes of 
administration of old drugs? Isn’t it obvious that 
combination of two anti-hypertensive drugs (of 
course, if efficacy of the combined drug can be 
proved by the inventor) provides better blood pressure 
control than separate ones or an extended release form 
of a drug provide an initial and then a gradual release 
of the drug for long periods of time in the body and 
accordingly reduce dosing frequency of the drug and 
its side effects? Isn’t it obvious that a polymorph with 
better tensile strength has better tabletability or a drug 
metabolite has a better excretion in the body? Briefly, 
these minor modified drugs (with minor or no 
substantive improvements in efficacy) due to lack of 
full requirements of an invention such as novelty and 
obviousness cannot be considered as new drugs, 
therefore, cannot be patented. A fundamental question 
in this regard is: Can an invention be patented more 
than once? It depends, from legal and regulatory 
perspectives, it can’t; but, from ever greening 
perspective, surely yes! Why not?  
It is claimed that originator manufacturers use 
these strategies in order to compensate the high costs 
of research and development of the new drugs. 
Because of differences in methods, data sources, time 
periods and lack of transparency, the actual cost of 
new drug R&D is unclear. For these reasons, different 
estimates of developing a new drug from R&D to the 
market (even more than 9 to 14-fold) from US$92 
million to US$883.6 million
61
 or from US$204 
million
62
 to US$2870 million
63 
have been reported by 
researchers. 
Despite wide varieties,not all of the costs involved 
are not only relevant to the research and development 
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of new drugs. Drug marketing is a big business and 
the steep rise in costs of new drug R&D is partially 
due to drug advertising including: direct-to-consumer 
(DTC) advertising and physicians' visits. However, 
advertising is a very influential factor in business of 
pharmaceutical industry. In the United States, 
pharmaceutical companies spent nearly 2 times more 
on marketing than R&D
64 
because for every $1 
invested by the industry in DTC advertising, the 
market produced a gain of $4.20.
65 
Figure 1 illustrates 
annual costs of DTC advertising spent by the US 
pharmaceutical industries.
66-68 
Pharmaceutical industries of the United States 
spent $12 million in 1980; $47 million in 1990 and 
$340 million in 1995 on DTC advertising (3,000% 
nearly increased during 15 years). In 1997, when the 
FDA issued the draft guidance on this topic, the DTC 
investment tripled to $1.2 billion in 1998
66
 and 
reached to $5 billion in 2017.
67-68 
The skyrocketing 
cost of DTC advertising directly affects the drug 
price. For instance, the cost of Plavix
®
 increased 
(considering Medicaid funds spent for Plavix
®
 in 
pharmacies) due to the need to regain the high costs 
of DTC advertising.
69
 
The originator manufacturers have also not been 
paid the same R&D costs (and not drug advertising 
costs) for these minor modifications of existing 
drugs? For example, AstraZeneca has not been  
paid the same R&D cost for Nexium
®
 as much  
as paid for Prilosec
®, 
similarly,
 
Pfizer has not been 
paid the same R&D cost for Effexor XR
® 
as much  
as paid for Effexor
®
. 
Pragmatic approaches to evergreening of patents 
are now seen in developed, developing and least 
developed countries.
70
 While there are various 
regulations in the United States (35 U.S.C 102(b),  
35 U.S.C 103(a) and 35 U.S.C 271 (e)) and Europe 
(Articles 54 and 56 which relate to novelty and 
inventive step, respectively) that restrict patent 
evergreening,
71
 but many developing countries 
including: Chile, South Africa, Brazil, Argentina and 
India don’t have efficient measures in order to prevent 
pharmaceutical patent evergreening.
72-75
 Lack of these 
measures urges to balance between public health 
interests and interests of patent owners
76
 and seeking 
suitable approaches to facilitate better access to drugs 
in developing countries.
77 
Prevention of 
pharmaceutical patent evergreening is particularly 
important for developing and least developed 
countries. For example, a new study revealed that 
poor and developing countries pay up to 30 times 
more for basic medicines (like acetaminophen or 
omeprazole) than other countries
78
 and average 
percentage savings of using generic drugs in some 
countries are very impressive (89% in Colombia and 
84% in Indonesia only for 9 medicines).
79 
Of course, 
some good efforts have been made by some countries 
to solve pharmaceutical patent evergreening, but these 
efforts are insufficient. The India’s 3(d) Section of the 
Patents Act is a good model and example. 
Section 3(d) states: “The mere discovery of a new 
form of a known substance which does not result in 
the enhancement of the known efficacy of that 
substance or the mere discovery of any new property 
or new use for a known substance or of the mere use 
of a known process, machine or apparatus unless 
such known process results in a new product or 
employs at least one new reactant. Explanation: 
“Salts, esters, ethers, polymorphs, metabolites, pure 
form, particle size, isomers, mixtures of isomers, 
complexes, combinations, and other derivatives of 
known substance shall be considered to be the same 
substance, unless they differ significantly in 
properties with regard to efficacy”. 
According to the Section 3(d) of the Patents Act, 
new forms of salts, esters, polymorphs, metabolites, 
change in particles size of drugs, difference in 
isomerism, isomers mixture, complex formation, 
combination of drugs and drug derivatives, do not 
consider as new drugs and cannot be patented, unless 
a significant change on the therapeutic properties of 
drugs has been occurred or these changes directly 
affect a great deal on the “efficacy” of the drugs. Such 
a law and regulation is helpful, but it would not be 
enough for supporting of public health in developing 
countries, because efficacy is not a quantified value 
and there is not any numerical standard for expression 
of efficacy. Therefore, lack of clarification and the 
scope definition of “enhanced efficacy” are entirely 
apparent. On the other hand, due to complexity of 
pharmaceutical technologies (process) and drug 
 
 
Fig. 1 — Costs of DTC advertising in the United States,  
1980-2017 
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formulations (product); it may not be very difficult to 
prove efficacy enhancement of new formulations of 
existing drugs.
80-82 
Thus, in addition to avoid using 
these arguable and misinterpretable terms, all terms 
and conditions must be carefully defined and clarified 
in the laws and regulations of the Patents Act in all 
countries of the world. 
Unfortunately, from the perspective of international 
flexibilities, it seems the system under the Paragraph 
6 of the Decision has not appropriate legal capacity 
for providing essential medicines and supporting 
public health and not only it is improbable to play a 
role in regulating of the drugs prices and incentives to 
invest on production of vital drugs, but also legally 
permits patent owners to prevent access to their 
patented drugs even in the case of compelling 
humanitarian reasons.
83
 
 
Conclusion 
A plenty of money is being paid by health systems 
of both developing and developed countries for the 
delay market entry of generic drugs. For this reason, 
PPE is the issue of global and accordingly, needs 
global solutions. But before any international action, 
because of territorial nature of patent exclusive rights, 
the easiest ways to fight PPE are: Exact examination 
of drug patent applications by health care 
professionals and examiners of patent office and 
establishment a close and effective relationship 
between these organizations in each country in order 
to support and promote of public health; 
Implementing the necessary amendments of the 
Patents Act in all countries in order to support of 
public health and; and Passing a law on prevention of 
PPE by legislatures in all countries. Such a law must 
be comprehensive and should be full extent, so that 
not only prevent all kinds of PPE including minor 
modifications of existing drugs, but also considers 
them unlawful and subjects to prosecute and heavy 
punishment due to endangering of public health. For 
example, for every attempt to PPE, the law provides 
suspension of one or more recently drug patents, an 
extra mulct payment or solving a health problem (in 
that country). At international level, it seems 
necessary to perform a feasibility study on the 
establishment of an international organization for 
examination all health-related patents (medicines, 
diagnostics, medical devices and vaccines) in order to 
help those countries that don’t have a suitable and 
efficient patent examination system. To conclude, a 
twenty-years period is sufficient time for originator 
manufacturers’ revenue and compensation of R&D 
costs, advertising costs and even lobbying costs and it 
will be no longer necessary to extent the patent life or 
ever-greening of pharmaceuticals. 
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